4-(4-cyclopropylimidazol-1-yl)-N-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide
C23H23N7O — CID 58103093
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-(4-cyclopropylimidazol-1-yl)-N-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide
4-(4-cyclopropylimidazol-1-yl)-N-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide (PubChem CID 58103093) has the molecular formula C23H23N7O and a molecular weight of 413.49 g/mol. Its IUPAC name is 4-(4-cyclopropylimidazol-1-yl)-N-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide.
Molecular Properties
| Compound Name | 4-(4-cyclopropylimidazol-1-yl)-N-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide |
|---|---|
| PubChem CID | 58103093 |
| Molecular Formula | C23H23N7O |
| Molecular Weight | 413.49 g/mol |
| Exact Mass | 413.20 |
| IUPAC Name | 4-(4-cyclopropylimidazol-1-yl)-N-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide |
| SMILES | CC(C)n1cnnc1-c1cccc(NC(=O)c2cc(-n3cnc(C4CC4)c3)ccn2)c1 |
| InChI | InChI=1S/C23H23N7O/c1-15(2)30-14-26-28-22(30)17-4-3-5-18(10-17)27-23(31)20-11-19(8-9-24-20)29-12-21(25-13-29)16-6-7-16/h3-5,8-16H,6-7H2,1-2H3,(H,27,31) |
| InChIKey | UIZCAIJJBDQQHD-UHFFFAOYSA-N |
| XLogP | 4.24 |
| TPSA | 90.52 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 413.49 |
| LogP ≤ 5 | 4.24 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 58103093 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.